YD Bio Limited (YDES) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 13.44 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 16.7% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While YDES currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.12) and Max Pain ($6.16) forces dealer call-delta covering toward $16.51.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
YD Bio Limited (YDES) dropped -6.53% to $5.87, trading at 30% of its 52-week range ($1.7 – $15.72). Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.
Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market cap
TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +16.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on YDES today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for YDES. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, YD Bio Limited (YDES) ranks #748 by composite RQD confidence (37/100, grade D-) and #477 by equity capitalization ($415.8M). Within this direct 5-issuer industry benchmark cohort, YDES leads on earnings valuation at N/A trailing P/E, while FLGT leads on capital efficiency and profitability with -6.8% ROIC and 40.6% gross margin. BDSX currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with YDES at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| YDES
ACTIVE
YD Bio Limited | D- | 37/100 | — | 28.1% | -20.0% | -6.53% | $415.8M | Benchmark Subject |
| FLGT Fulgent Genetics Inc. | E | 34/100 | — | 40.6% | -6.8% | +0.74% | $596.5M | /flgt-vs-ydes → |
| BDSX Biodesix Inc. | D | 44/100 | — | — | -35.0% | +8.14% | $260.8M | /bdsx-vs-ydes → |
| TLSI TriSalus Life Sciences Inc. | E | 34/100 | — | 84.6% | -35.0% | -1.78% | $237.7M | /tlsi-vs-ydes → |
| XGN Exagen Inc. | E | 31/100 | — | 58.3% | -35.0% | +3.57% | $210.8M | /xgn-vs-ydes → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), YD Bio Limited (YDES) reported GAAP revenue of $596.8K (+16.9% vs. FY2024 revenue of $510.4K , and +70.5% cumulative change since FY2023) , GAAP net income of -$8.3M, operating cash flow of -$6.6M, and free cash flow of -$8.0M (-519.4% YoY). On the balance sheet, YDES closed FY2025 with $13.8M in total assets against $0 in total debt (Altman Z-Score: 13.44, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $596.8K | -$8.3M | -$6.6M | -$8.0M | $13.8M | — |
| FY2024 (FY) | 2024-12-31 | $510.4K | -$1.4M | -$1.2M | -$1.3M | $6.9M | — |
| FY2023 (FY) | 2023-12-31 | $350.1K | $13.6K | -$55.7K | -$55.7K | — | — |
As of 2026-11-01, YD Bio Limited (NASDAQ: YDES) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $5.87 (-6.53% 1D, market cap $415.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, YDES ranks #748 in composite RQD confidence.
Within the Health Care sector (Medical Specialities), YDES carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -20.0%. By comparison, FLGT (Fulgent Genetics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -6.8%, cap $596.5M) and BDSX (Biodesix Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M). Among the 5-stock peer group, YDES leads on earnings multiple (N/A) while FLGT leads on capital efficiency (-6.8% ROIC).
Per YDES's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002011674), YD Bio Limited generated $596.8K in revenue (+16.9% YoY), -$8.3M in net income, and -$8.0M in free cash flow against $13.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
YDES last traded at $5.87 (-6.53% on volume of 96,187 shares), positioning the stock +14.65% above its 50-day simple moving average ($5.12) and +6.34% above its 200-day simple moving average ($5.52). Across its 52-week range of $1.70 to $15.72, YDES sits at the 29.7% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.14 to $6.60).
Why YDES Stock dropped -6.53% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.